ERIS Lifescience

ERIS26 Apr 2024

Pharmaceuticals

₹

+10.65 (+1.21%)

Lowest Today

Highest Today

Prev. Close

Today’s Open

52 Week High

52 Week Low

BUY

SELL

To Invest in ERIS Lifescience

ERIS Lifescience

Pharmaceuticals

ERIS26 Apr 2024

₹

+10.65 (+1.21%)

OverviewFundamentals

Corporate action

Peer comparison

Income Sheet

Balance sheet

Cash flow

Share holding

About Us

Corporate Action

These are actions taken by a company that impact the shareholders value directly. It is an event that brings material changes to a company and affects its stakeholders.

All

Dividends

Bonus

Splits

Others

Ex-Date	Type	Description	Record Date
05-Aug-2022	D	Eris Lifesciences Ltd has informed BSE that the Board of Directors of the Company, in their meeting held on August 05, 2022, inter alia, approved/took on record the following : Declaration of interim dividend of Rs. 7.35/- (at the rate of 735%) on each fully paid-up equity share of Re. 1/- for the Financial Year 2022-2023.	11-Aug-2022
29-Jul-2021	D	Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby inform you that the Board of Directors of the Company, in their meeting held today, i.e., July 29, 2021 inter alia, duly approved / took on record the following: Declaration of interim dividend of Rs. 6.01 (at the rate of 601%) on each fully paid-up equity share of Re. 1/- for the Financial Year 2021-2022;	05-Aug-2021
04-Aug-2020	D	Eris Lifesciences Ltd has informed BSE that the Board of Directors of the Company at its meeting held on August 04, 2020, inter alia, duly approved / took on record the following: - Declaration of Interim Dividend of Rs 5.50/- (at the rate of 550%) on each fully paid-up equity share of Re.1/- for the Financial Year 2020-21.	13-Aug-2020
11-Mar-2020	D	Eris Lifesciences Ltd has informed BSE that the Board of Directors of the Company at its meeting held on March 11, 2020 duly approved the declaration of Interim Dividend of Rs. 2.87/- (at the rate of 287%) on each fully paid-up equity share of Re. 1/- for the Financial Year 2019-20.	19-Mar-2020
19-Apr-2024	BC	Trading Members of the Exchange are hereby informed that the further new securities issued by the under mentioned companies are listed and admitted for trading on the Exchange with effect from Monday	22-Apr-2024
14-Mar-2024	BC	Trading Members of the Exchange are hereby informed that the under mentioned new securities issued by Eris Lifesciences Limited on private placement basis is listed and admitted to dealings on the BS	14-Mar-2024
14-Mar-2024	BC	Dear Sir/Madam, Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby inform you that the Board of Directors of the Company, in its meet	14-Mar-2024
06-Feb-2024	BC	Eris Lifesciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/02/2024 inter alia to consider and approve the standalone and consolidated unaudited	13-Feb-2024
08-Feb-2024	BC	UTI Mutual Fund	07-Feb-2024

No Rights has been declared by ERIS

Book Closure

Record Date	Split Date	Purpose
22-Apr-2024	-	Trading Members of the Exchange are hereby informed that the further new securities issued by the under mentioned companies are listed and admitted for trading on the Exchange with effect from Monday
14-Mar-2024	-	Trading Members of the Exchange are hereby informed that the under mentioned new securities issued by Eris Lifesciences Limited on private placement basis is listed and admitted to dealings on the BS
14-Mar-2024	-	Dear Sir/Madam, Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby inform you that the Board of Directors of the Company, in its meet
13-Feb-2024	-	Eris Lifesciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/02/2024 inter alia to consider and approve the standalone and consolidated unaudited
07-Feb-2024	-	UTI Mutual Fund

Peer Comparison

These are actions taken by a company that impact the shareholders value directly. It is an event that brings material changes to a company and affects its stakeholders.

Scrip Name	Price	Daily Change	M.Cap (Cr)	1 Year Returns %	P/E (TTM)	PB Ratio
ERIS Lifesciences Ltd ₹892.60(+10.65/1.21%)	892.60	+10.65	12,143.60	44.71	34.89	4.95
Astrazeneca Pharma India Ltd ₹5,415.40(+81.55/1.53%)	5,415.40	+81.55	13,538.50	71.09	84.88	20.67
Bliss GVS Pharma Ltd ₹122.60(+5.85/5.01%)	122.60	+5.85	1,283.51	60.79	18.80	1.31
Cipla Ltd ₹1,409.40(+4.00/0.28%)	1,409.40	+4.00	113,794.25	54.54	34.60	4.40
Abbott India Ltd ₹25,864.85(+201.35/0.78%)	25,864.85	+201.35	54,962.81	15.87	47.98	17.68
Amrutanjan Health Care Ltd ₹680.85(-8.80/-1.28%)	680.85	-8.80	1,968.38	13.21	44.73	7.51

Income Sheet

These are actions taken by a company that impact the shareholders value directly. It is an event that brings material changes to a company and affects its stakeholders.

Standalone

Consolidated

Column	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22
Gross Sales	315.96	402.26	404.29	308.36	326.76	349.98
Excise Duty	0.00	0.00	0.00	0.00	0.00	0.00
Net Sales	315.96	402.26	404.29	308.36	326.76	349.98
Other Operating Income	8.45	7.45	7.00	6.23	5.25	5.39
Other Income	3.43	6.98	4.03	4.26	3.48	6.15
Total Income	327.85	416.68	415.31	318.84	335.49	361.52
Total Expenditure	249.98	265.22	255.79	203.09	205.62	214.32
PBIDT	77.87	151.47	159.53	115.75	129.87	147.20
Interest	15.14	6.55	6.84	2.96	3.14	7.49
PBDT	62.73	144.92	152.69	112.79	126.73	139.72
Depreciation	28.08	25.00	20.16	17.28	16.50	15.90
Tax	5.83	21.84	21.74	17.01	19.23	20.87
Deferred Tax	-2.84	-19.73	0.04	-9.34	-8.38	-12.26
Reported Profit After Tax	31.66	117.81	110.74	87.84	99.38	115.20
Extra-ordinary Items	0.00	0.00	0.00	0.00	0.00	0.00
Adjusted Profit After Extra-ordinary item	31.66	117.81	110.74	87.84	99.38	115.20

EPS (Unit Curr.)	2.33	8.66	8.14	6.46	7.31	8.47
EPS (Adj) (Unit Curr.)	2.33	8.66	8.14	6.46	7.31	8.47
Calculated EPS (Unit Curr.)	2.33	8.66	8.14	6.46	7.31	8.47
Calculated EPS (Adj) (Unit Curr.)	2.33	8.66	8.14	6.46	7.31	8.47
Calculated EPS (Ann.) (Unit Curr.)	9.31	34.64	32.57	25.84	29.23	33.88
Calculated EPS (Adj) (Ann.) (Unit Curr.)	9.31	34.64	32.57	25.84	29.23	33.88
Book Value (Unit Curr.)	0.00	0.00	0.00	0.00	0.00	0.00
Dividend (%)	0.00	0.00	0.00	0.00	0.00	0.00
Equity	13.60	13.60	13.60	13.60	13.60	13.60
Reserve & Surplus	0.00	0.00	0.00	0.00	0.00	0.00
Face Value	1.00	1.00	1.00	1.00	1.00	1.00

Public Shareholding (No. Of Shares)	0.00	0.00	0.00	0.00	0.00	0.00
Public Shareholding (% in Equity)	0.00	0.00	0.00	0.00	0.00	0.00

Pledged/Encumbered - No. of Shares	0.00	0.00	0.00	0.00	0.00	0.00
Pledged/Encumbered - % in Total Promoters Holding	0.00	0.00	0.00	0.00	0.00	0.00
Pledged/Encumbered - % in Total Equity	0.00	0.00	0.00	0.00	0.00	0.00

Non Encumbered - No. of Shares	0.00	0.00	0.00	0.00	0.00	0.00
Non Encumbered - % in Total Promoters Holding	0.00	0.00	0.00	0.00	0.00	0.00
Non Encumbered - % in Total Equity	0.00	0.00	0.00	0.00	0.00	0.00

PBIDTM(%)	24.65	37.65	39.46	37.54	39.74	42.06
PBDTM(%)	19.85	36.03	37.77	36.58	38.78	39.92
PATM(%)	10.02	29.29	27.39	28.49	30.41	32.92

Column	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22
Gross Sales	483.48	500.52	460.03	396.59	417.84	455.33
Excise Duty	0.00	0.00	0.00	0.00	0.00	0.00
Net Sales	483.48	500.52	460.03	396.59	417.84	455.33
Other Operating Income	2.82	4.78	6.59	6.21	5.42	5.18
Other Income	4.20	3.48	0.99	1.00	2.24	5.17
Total Income	490.49	508.78	467.61	403.80	425.50	465.68
Total Expenditure	310.79	324.16	296.88	283.90	286.06	309.06
PBIDT	179.71	184.63	170.73	119.90	139.44	156.62
Interest	18.12	16.30	17.36	8.87	3.00	7.07
PBDT	161.59	168.33	153.38	111.03	136.44	149.55
Depreciation	45.72	42.09	40.89	35.13	29.90	28.62
Minority Interest Before NP	0.00	0.00	0.00	0.00	0.00	0.00
Tax	19.38	25.38	21.74	17.00	15.67	21.72
Deferred Tax	-4.97	-21.45	-2.90	-2.58	-9.37	-20.16
Reported Profit After Tax	101.46	122.31	93.65	61.48	100.23	119.38
Minority Interest After NP	-1.28	-1.12	-1.21	-3.94	-1.63	-0.93
Net Profit after Minority Interest	102.74	123.43	94.86	65.42	101.86	120.30

Extra-ordinary Items	0.00	0.00	0.00	0.00	0.00	0.00
Adjusted Profit After Extra-ordinary item	102.74	123.43	94.86	65.42	101.86	120.30

EPS (Unit Curr.)	7.55	9.08	6.97	4.81	7.49	8.84
Book Value (Unit Curr.)	0.00	0.00	0.00	0.00	0.00	0.00
Dividend (%)	0.00	0.00	0.00	0.00	0.00	0.00
Equity	13.60	13.60	13.60	13.60	13.60	13.60

Public Shareholding (Number)	0.00	0.00	0.00	0.00	0.00	0.00
Public Shareholding (%)	0.00	0.00	0.00	0.00	0.00	0.00

Pledged/Encumbered - No. of Shares	0.00	0.00	0.00	0.00	0.00	0.00
Pledged/Encumbered - % in Total Promoters Holding	0.00	0.00	0.00	0.00	0.00	0.00
Pledged/Encumbered - % in Total Equity	0.00	0.00	0.00	0.00	0.00	0.00

Non Encumbered - No. of Shares	0.00	0.00	0.00	0.00	0.00	0.00
Non Encumbered - % in Total Promoters Holding	0.00	0.00	0.00	0.00	0.00	0.00
Non Encumbered - % in Total Equity	0.00	0.00	0.00	0.00	0.00	0.00

PBIDTM(%)	37.17	36.89	37.11	30.23	33.37	34.40
PBDTM(%)	33.42	33.63	33.34	28.00	32.65	32.84
PATM(%)	20.99	24.44	20.36	15.50	23.99	26.22

Balance Sheet

These are actions taken by a company that impact the shareholders value directly. It is an event that brings material changes to a company and affects its stakeholders.

Standalone

Consolidated

Column	Mar 23	Mar 22	Mar 21	Mar 20	Mar 19	Mar 18
SOURCES OF FUNDS :
Share Capital	13.60	13.59	13.58	13.58	13.75	13.75
Reserves Total	2208.29	1904.51	1561.89	1286.12	1142.26	854.43
Equity Share Warrants	0.00	0.00	0.00	0.00	0.00	0.00
Equity Application Money	0.00	0.45	0.00	0.00	0.00	0.00
Total Shareholders Funds	2221.89	1918.55	1575.47	1299.70	1156.01	868.18
Secured Loans	264.47	0.00	0.00	0.00	175.92	376.08
Unsecured Loans	52.40	0.00	0.00	0.00	0.00	0.00
Total Debt	316.87	0.00	0.00	0.00	175.92	376.08
Total Liabilities	2538.76	1918.55	1575.47	1299.70	1331.93	1244.26
APPLICATION OF FUNDS :
Gross Block	1089.83	778.40	716.88	695.65	551.81	532.93
Less : Accumulated Depreciation	192.02	136.40	132.55	95.01	67.96	43.19
Less:Impairment of Assets	0.00	0.00	0.00	0.00	0.00	0.00
Net Block	897.81	642.00	584.33	600.64	483.85	489.74
Lease Adjustment	0.00	0.00	0.00	0.00	0.00	0.00
Capital Work in Progress	0.34	2.98	1.56	4.37	2.73	0.00
Producing Properties	0.00	0.00	0.00	0.00	0.00	0.00
Investments	996.52	777.72	531.37	320.30	580.47	545.60
Current Assets, Loans & Advances	0.00	0.00	0.00	0.00	0.00	0.00
Inventories	63.70	84.79	64.85	65.46	74.70	57.52
Sundry Debtors	229.22	137.56	113.76	140.82	75.90	60.50
Cash and Bank	47.65	46.11	32.66	64.95	6.47	8.81
Loans and Advances	181.50	212.02	161.98	104.09	86.60	95.60
Total Current Assets	522.07	480.47	373.24	375.32	243.67	222.43
Less : Current Liabilities and Provisions	0.00	0.00	0.00	0.00	0.00	0.00
Current Liabilities	114.10	123.38	110.08	114.34	94.06	89.25
Provisions	62.27	42.86	34.38	35.10	20.68	18.57
Total Current Liabilities	176.37	166.24	144.46	149.44	114.73	107.82
Net Current Assets	345.70	314.23	228.78	225.89	128.94	114.61
Miscellaneous Expenses not written off	0.00	0.00	0.00	0.00	0.00	0.00
Deferred Tax Assets	399.14	350.70	297.27	240.62	196.28	121.80
Deferred Tax Liability	125.36	114.59	100.52	76.46	58.50	26.55
Net Deferred Tax	273.78	236.11	196.75	164.16	137.78	95.25
Total Assets	2514.16	1973.05	1542.78	1315.36	1333.77	1245.21
Contingent Liabilities	25.39	24.34	18.32	15.81	15.29	14.12

Column	Mar 23	Mar 22	Mar 21	Mar 20	Mar 19	Mar 18
SOURCES OF FUNDS :
Share Capital	13.60	13.59	13.58	13.58	13.75	13.75
Reserves Total	2182.39	1894.27	1562.84	1282.76	1136.77	847.56
Equity Share Warrants	0.00	0.00	0.00	0.00	0.00	0.00
Equity Application Money	0.00	0.45	0.00	0.00	0.00	0.00
Total Shareholders Funds	2195.99	1908.31	1576.42	1296.34	1150.52	861.31
Minority Interest	24.69	-0.11	0.00	0.00	18.31	24.67
Secured Loans	699.45	45.00	0.00	0.00	176.42	376.80
Unsecured Loans	177.26	39.41	6.78	0.00	0.00	0.00
Total Debt	876.71	84.41	6.78	0.00	176.42	376.80
Policy Holders Fund	0.00	0.00	0.00	0.00	0.00	0.00
Other Liabilities	62.36	37.80	37.44	40.67	27.31	22.19
Total Liabilities	3159.75	2030.41	1620.64	1337.01	1372.56	1284.97
APPLICATION OF FUNDS :
Gross Block	2843.17	1091.96	1005.80	983.89	838.26	819.52
Less: Accumulated Depreciation	275.07	174.02	151.92	109.04	77.73	48.43
Less: Impairment of Assets	0.00	0.00	0.00	0.00	0.00	0.00
Net Block	2568.10	917.94	853.88	874.85	760.53	771.09
Lease Adjustment	0.00	0.00	0.00	0.00	0.00	0.00
Capital Work in Progress	21.72	26.99	1.56	4.37	2.73	0.00
Producing Properties	0.00	0.00	0.00	0.00	0.00	0.00
Investments	36.70	520.39	294.04	77.99	355.85	365.37
Current Assets, Loans & Advances	0.00	0.00	0.00	0.00	0.00	0.00
Inventories	131.44	117.91	94.47	69.48	82.65	65.45
Sundry Debtors	292.71	160.97	140.49	156.88	83.98	66.64
Cash and Bank	58.46	52.33	38.28	67.33	7.51	10.64
Loans and Advances	252.11	196.58	143.42	111.15	92.71	62.22
Total Current Assets	734.71	527.79	416.65	404.83	266.84	204.95
Less : Current Liabilities and Provisions	0.00	0.00	0.00	0.00	0.00	0.00
Current Liabilities	176.60	149.58	129.36	127.50	106.56	103.23
Provisions	73.34	46.05	35.24	37.20	22.84	19.63
Total Current Liabilities	249.94	195.64	164.60	164.69	129.40	122.86
Net Current Assets	484.77	332.15	252.05	240.14	137.44	82.09
Miscellaneous Expenses not written off	0.00	0.00	0.00	0.00	0.00	0.00
Deferred Tax Assets	273.95	243.13	200.63	299.40	144.79	100.57
Deferred Tax Liability	257.64	46.09	49.54	179.10	51.70	52.27
Net Deferred Tax	16.31	197.04	151.09	120.30	93.09	48.30
Other Assets	32.14	35.90	68.03	19.35	22.91	18.11
Total Assets
Contingent Liabilities	28.39	24.51	19.60	17.10	16.58	14.50

Cash Flow

These are actions taken by a company that impact the shareholders value directly. It is an event that brings material changes to a company and affects its stakeholders.

PARTICULARS	Mar 2023	Mar 2022	Mar 2021	Mar 2020	Mar 2019
Cash and Cash Equivalents at Beginning of the year	44.70	31.35	64.93	6.46	8.81
Net Cash from Operating Activities	322.33	369.41	395.41	265.25	216.31
Net Cash Used In Investing Activities	-513.30	-267.64	-347.86	126.74	2.08
Net Cash Used In Financing Activities	193.75	-88.42	-81.13	-333.52	-220.74
Net Inc./Dec In Cash And Cash Equivalents	2.78	13.36	-33.58	58.47	-2.34
Cash And Cash Equivalents At End Of The Year	47.48	44.70	31.35	64.93	6.46

Share Holding

These are actions taken by a company that impact the shareholders value directly. It is an event that brings material changes to a company and affects its stakeholders.

Promoter Shareholding

54.90%

FII Shareholding

14.27%

DII Shareholding

15.63%

Public Shareholding

15.19%

**Promoter pledged shareholding 54.90%

About ERIS Lifesciences Ltd

ERIS Lifesciences Ltd is in the Pharmaceuticals sector, having a market capitalization of Rs. 12143.6 crores. It has reported a sales of Rs. 315.96 crores and a net profit of Rs. 31.66 crores for the quarter ended December 2018. The company management includes Amit Indubhushan Bakshi, Amit Indubhushan Bakshi,Kaushal Kamlesh Shah,Inderjeet Singh Negi,Krishnakumar Vaidyanathan,Sujesh Vasudevan,Prashant Gupta,Rajeev Narotam Dalal,Kalpana Unadkat (ERIS Lifesciences Ltd) among others.

Chairman

Amit Indubhushan Bakshi

Registered office

8th Floor Commerce House -IV,Prahladnagar 100 FT Road,Ahmedabad,Gujarat,380015

FAX :91-79-48903474

Background

Incorporation Year2007

Face Value₹1

Market Lot1

How to buy ERIS Lifescience shares on nse?

To buy ERIS Lifescience shares in Motilal Oswal, you just need to open a demat account and get your KYC documents verified

What is the ERIS Lifescience share price today?

The ERIS Lifescience shares price on nse is Rs.892.6 today.

What is the market cap of ERIS Lifescience shares on BSE ?

The company has a market capitalization of Rs.12143.60Cr

What is the PE & PB ratio of ERIS Lifescience shares ?

PE is 34.89 and PB is 4.95

What is the 52 Week High and Low of ERIS Lifescience shares?

ERIS Lifescience stock price high: Rs.971 ERIS Lifescience stock price low: Rs.605.2

What is the price of ERIS Life Sciences stocks on BSE?

The price of ERIS Life Sciences as of the end of day 17th April 2023 was INR 612.6 on BSE.

Is it safe to buy ERIS Life Sciences?

ERIS Life Sciences net profit has increased from Rs. 291.15 crores to Rs. 405.79 crores in the last four years. And the company's sales revenue has grown from Rs.982.6 crores to Rs. 1347 crores in the last four years.

ERIS Life Sciences stock 52 weeks low is Rs.551.3 and high is Rs.749.8.

Equity investment is a risk like any other investment and it is advisable to take professional advice before investing.

What is the current market value per stock of ERIS Life Sciences?

The current market value (or market capitalization) of ERIS Life Sciences is approximately Rs. 8.33K crores as on 17th April 2023.

Does ERIS Life Science have any debts?

ERIS Life Sciences has a debt-to-equity ratio of 0.13.

Will ERIS Life Science stock price increase?

Eris Life Sciences is a pharmaceutical company based in India that focuses on developing, manufacturing, and marketing branded pharmaceutical products across various therapeutic areas. The company's products are sold in India and other countries, including Nepal, Sri Lanka, and Mauritius.

However, it is near impossible to predict the future movements of stock prices, as they are linked to a wide range of variables, including market trends, economic conditions, company performance, and global events.

It's imperative to conduct thorough research and due diligence in making any investment decisions. And to consider several relevant factors that could impact the company's future prospects.

Should I buy or sell ERIS Life Science?

ERIS Life Sciences stock has given a positive return of 33.61% over the last 3 years and a negative return of -12.85% over the past 12 months.

Selling or buying of specific stock or stocks depends on your personal financial goals and risk tolerance.